Key Points
- Rahul Khara sold 1,000 shares of Disc Medicine on Jan. 20 at $69.74 for $69,740 and had earlier sold 6,500 shares on Jan. 2 at $78.69, leaving him with 37,793 shares (a 2.58% reduction) valued at about $2.636 million.
- Disc Medicine has a $2.83 billion market cap and a negative PE (-14) after reporting an EPS miss (‑$1.77 vs. ‑$1.48 expected), but analysts maintain a consensus rating of Moderate Buy with an average target price of $119.45.
Disc Medicine, Inc. (NASDAQ:IRON - Get Free Report) insider Rahul Khara sold 1,000 shares of the stock in a transaction on Tuesday, January 20th. The stock was sold at an average price of $69.74, for a total value of $69,740.00. Following the completion of the transaction, the insider owned 37,793 shares of the company's stock, valued at approximately $2,635,683.82. This trade represents a 2.58% decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through this link.
Rahul Khara also recently made the following trade(s):
- On Friday, January 2nd, Rahul Khara sold 6,500 shares of Disc Medicine stock. The shares were sold at an average price of $78.69, for a total transaction of $511,485.00.
Disc Medicine Stock Up 1.2%
NASDAQ:IRON opened at $74.89 on Thursday. The company has a debt-to-equity ratio of 0.05, a current ratio of 23.45 and a quick ratio of 23.45. The firm's 50-day moving average price is $84.83 and its 200-day moving average price is $72.97. The company has a market capitalization of $2.83 billion, a PE ratio of -14.00 and a beta of 0.87. Disc Medicine, Inc. has a 1-year low of $30.82 and a 1-year high of $99.50.
Disc Medicine (NASDAQ:IRON - Get Free Report) last announced its quarterly earnings data on Thursday, November 6th. The company reported ($1.77) earnings per share for the quarter, missing analysts' consensus estimates of ($1.48) by ($0.29). On average, equities analysts predict that Disc Medicine, Inc. will post -4.07 EPS for the current fiscal year.
Analyst Upgrades and Downgrades
A number of equities research analysts have recently commented on the company. Weiss Ratings reissued a "sell (d-)" rating on shares of Disc Medicine in a research note on Wednesday, October 8th. Wedbush reiterated an "outperform" rating on shares of Disc Medicine in a research note on Thursday, January 15th. Wells Fargo & Company increased their price objective on shares of Disc Medicine from $91.00 to $109.00 and gave the company an "overweight" rating in a research report on Tuesday, December 16th. National Bankshares set a $153.00 target price on shares of Disc Medicine in a report on Friday, October 17th. Finally, UBS Group reiterated an "overweight" rating on shares of Disc Medicine in a report on Thursday, January 15th. Eleven investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, the company presently has a consensus rating of "Moderate Buy" and an average target price of $119.45.
Check Out Our Latest Stock Analysis on Disc Medicine
Hedge Funds Weigh In On Disc Medicine
Several hedge funds and other institutional investors have recently bought and sold shares of the stock. Vanguard Group Inc. grew its stake in shares of Disc Medicine by 3.7% in the third quarter. Vanguard Group Inc. now owns 1,448,059 shares of the company's stock worth $95,688,000 after acquiring an additional 51,323 shares during the period. JPMorgan Chase & Co. boosted its holdings in Disc Medicine by 11.1% in the second quarter. JPMorgan Chase & Co. now owns 843,616 shares of the company's stock worth $44,678,000 after purchasing an additional 84,278 shares during the last quarter. Geode Capital Management LLC grew its position in Disc Medicine by 4.7% in the 2nd quarter. Geode Capital Management LLC now owns 598,589 shares of the company's stock worth $31,705,000 after purchasing an additional 26,605 shares during the period. Vestal Point Capital LP raised its stake in Disc Medicine by 257.1% during the 3rd quarter. Vestal Point Capital LP now owns 500,000 shares of the company's stock valued at $33,040,000 after buying an additional 360,000 shares during the last quarter. Finally, Adage Capital Partners GP L.L.C. lifted its holdings in shares of Disc Medicine by 50.0% during the 2nd quarter. Adage Capital Partners GP L.L.C. now owns 450,000 shares of the company's stock valued at $23,832,000 after buying an additional 150,000 shares during the period. Institutional investors own 83.70% of the company's stock.
Disc Medicine Company Profile
(
Get Free Report)
Disc Medicine, Inc (NASDAQ: IRON) is a clinical-stage biotechnology company focused on discovering and developing precision medicines that restore normal cellular function in severe genetic and acquired diseases. The company employs a chemistry-driven approach to identify small molecules that selectively modulate RNA-binding proteins or splicing regulatory pathways. By leveraging proprietary screening and medicinal chemistry platforms, Disc Medicine aims to address diseases with high unmet medical needs and limited treatment options.
The company's pipeline is anchored by lead programs targeting neuromuscular and hematological disorders.
Featured Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
